Bridge is an ambitious company aiming to be revenue generating within 18 months by taking the lead project to exit, via out-licencing or trade sale, by investing in the innovative programs to treat serious inflammatory disorders.
We have licenced two very important components that we plan to combine to form a range of therapies aimed at treating serious inflammatory diseases:
Highly potent and highly specific novel peptide (“small protein”) anti-inflammatory therapeutics
Safe, nanoparticle delivery polmer, that will take the peptides into human cells and switch off inflammation
By combining these two important components to form its lead compound JEL3108, we will create a new medicine to safely treat the life threatening and disabling inflammatory disease called inflammatory bowel disease (IBD).
Bridge is currently seeking a total of $16,000,000 'Series A' funding to drive the lead compound through to approved IND/CTA. Read more investment detail here.
Bridge was incorporated in late 2016 combining expert in-house resources with selected outsourced partners and collaborators. In 2017 Bridge gained exclusive world-wide licences to develop Astra-Zeneca peptide compounds and a clinically safe nano-particle delivery technology. We will take this combination from preclinical research to de-risked human clinical proof of concept trials, which employ cutting-edge adaptive clinical trial designs to expedite clinical trial delivery. In this way, Bridge aims to avoid much of the late stage efficacy failures experienced by large pharma companies.
If you would like to make a donation to Bridge Biotec to help us advance our research into inflammation treatments, please use the donate button below.